vimarsana.com

Page 30 - அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

These are the rare symptoms to watch for if you recently got the Johnson & Johnson vaccine

These are the rare symptoms to watch for if you recently got the Johnson & Johnson vaccine Updated: 8:01 AM EDT Apr 14, 2021 Sandee LaMotte, CNN Share Updated: 8:01 AM EDT Apr 14, 2021 Hide Transcript Show Transcript BUT I DO THINK IT’S GONNA UNDERMINE CONFIDENCE IN A MULTITUDE OF OF WAYS ADMINISTRATION OF THE JOHNSON. & JOSEPHINE HALTED TUESDAY ON THE RECOMMENDATION OF THE CDC AND THE FDA AFTER SIX WOMEN WHO RECEIVED THE SHOT DEVELOPED AN EXTREMELY RARE TYPE OF BLOOD CLOT ANYTHING THAT HAS HAPPENED TO YOU AFTER A VACCINE COULD BE AN ADVERSE EVENT. AND SO THE FDA IN THE CDC DOES TAKE THAT VERY SERIOUSLY AND MAKES SURE THAT THEY DO. DUE DILIGENCE MEETING. THEY’LL INVESTIGATE THIS TO SEE IF THERE IS ANY CORRELATION BETWEEN THE VACCINE AND THESE EVENTS WITH SEVEN MILLION SHOTS ADMINISTERED DR. LEMAY SAYS EVEN SIX CASES NEED TO BE INVESTIGATED IN THE SPIRIT OF SAFETY AND TRANSPARENCY TO ME. IT’S THE RIGHT THING TO DO TO ME. I’M ALSO POSITIVE

Johnson & Johnson vaccine: Rare blood clot symptoms explained

Johnson & Johnson vaccine: Rare blood clot symptoms explained CNN 3 hrs ago If you experience a severe headache that does not go away, significant abdominal or leg pain that does not subside, or increasing shortness of breath, health officials want you to call your doctor immediately. Those could be signs of an extremely rare, severe type of clot that may be linked to the Johnson & Johnson vaccine so rare that only six cases have been reported in the United States out of the approximately 7 million Johnson & Johnson doses administered to date. However, if you received the J&J vaccine more than a month ago, the risk is very low, said Dr. Anne Schuchat, principal deputy director of the US Centers for Disease Control and Prevention, during a virtual briefing on Tuesday.

Researchers Identify Potential Targets for Novel Treatments for Lung Cancer

Date Time Researchers Identify Potential Targets for Novel Treatments for Lung Cancer Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. A team of investigators led by Elena Levantini, PhD, a research associate in Hematology-Oncology in the laboratory of Daniel Tenen MD, at Beth Israel Deaconess Medical Center (BIDMC), evaluated a novel agent, PTC596, capable of decreasing tumor growth in preclinical studies performed on a mouse model of mutant K-RAS lung cancer. The research – performed in collaboration with the Cancer Science Institute of Singapore at the National University of Singapore (CSI NUS) – were published today in the journal Communications Biology. The findings, which represent a comprehensive snapshot of the tumor’s components, will facilitate the d

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.